Eli Lilly

Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.